Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis
BackgroundIn the first-line treatment of advanced non-small cell lung cancer (NSCLC), for those patients with negative PD-L1 expression, which treatment strategy has the better efficacy and safety between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors (ICIs) is still...
Main Authors: | Jiaqi Li, Yingjie Chen, Fan Hu, Huiping Qiang, Qing Chang, Jialin Qian, Yinchen Shen, Yong Cai, Tianqing Chu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1001503/full |
Similar Items
-
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
by: Shinada K, et al.
Published: (2023-02-01) -
Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Patrícia S. Sobral, et al.
Published: (2023-03-01) -
Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
by: Wei Chen, et al.
Published: (2023-08-01) -
The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01) -
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
by: Koichi Furukawa, et al.
Published: (2020-08-01)